Lucideon, an international materials development organisation has welcomed five researchers from the Institute of Biomaterials at the Friedrich Alexander University of Erlangen-Nuremberg, Germany to its headquarters in Stoke-on-Trent to develop new anti-bacterial materials.
The five researchers, supervised by Prof Aldo Boccaccini in Germany, are working with Lucideon staff members Mark Cresswell, Phil Jackson and Chris Lovell to develop a range of materials with intrinsic anti-bacterial properties.
The researchers are: Muhammad Maqbool (Substituted Hydroxyapatite); Agata Łapa (Bioactive Phosphate Glass),; Seray Kaya (Bioactive Silica Glass); Lukas Gritsch (Bioresorbable Antibacterial Polyesters), and Binh Thi Thanh Phan (Biodegradable and Bioresorbable Polyester).
(left - right) Binh Thi Thanh Phan, Muhammad Maqbool, Lukas Gritsch, Seray Kaya, Phil Jackson, Chris Lovell, Agata Lapa, Mark Cresswell.
Lucideon is one of nine companies, clinics and universities involved in the HyMedPoly project ‘Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications,’ a collaboration training PhD researchers in the development of drug-free antibacterial materials used for medical applications, such as wound care and implants.
The project is funded under the European Commission’s Marie Skłodowska-Curie Innovative Training Networks program.
Stuart MacLachlan, Head of research at Lucideon and the HyMedPoly project manager, said: “It’s great to have the researchers at Lucideon and to see them settling into their projects. They’re learning new skills working with our materials development teams and they’re bringing a lot to the company too.
“HyMedPoly covers a vital area of research. Infection has become one of the toughest problems in the medical world. As bacteria become more resistant to drugs and there are fewer effective antibiotics, new materials with intrinsic antibacterial properties have an important role.”